The article presents information on the approval of the first genetic medicine alipogene tiparvovec (Glybera) for the treatment of lipoprotein lipase deficiency in the European market by the European Medicines Agency (EMA). It mentions the medicine to be the most expensive approved medicine for treatment and mentions the manufacturer of the drug UniQure BV at maintaining patient registry and risk management plan.